of cases (control group) Control group: retrospective 17 (10) 7 (none) 14 (none) 8 (none) 16 (none) 11 (none) Primary disease (no. of cases) FSGS (14/9) MCNS(3/1) MN (3) MCNS(2) IgAGN (1) FSGS (14) PSL
resistant FSGS(6) MCNS (1) MN + FSGS (1) FSGS (13) MN (3) FSGS (11) PSL, Selleck Salubrinal CyA resistant No. of Treatment 2/w × 3 1/w × 6 Total 12 2/w × 3 1/w × 7 Total 13 2/w × 3 Total 6 2-13 7.3 (average) 2/w × 3 Total 6 2/w × 3 1/w × 6 Total 12 Concomitant treatment (no. of cases) PSL 1.0 mg/kg none (4) PSL(1) PSL + CyA (2) PSL 0.8 mg/kg PSL/pulse 1.0 mg/kg PSL (14) immunosuppressant (10) PSL 1.0 mg/kg Clinical efficacy Remission 9 Partial remission 4 no effect 4 Remission 2 Partial remission 4 no effect 1 Responded 8 no effect 6 Remission 4 Partial remission 1 no effect 3 Improved 7 Unchanged 3 Worsened
3 unjudgemental 3 Remission 5 Partial remission 2 Efficacy rate 76 % 86 % 57 % 63 % FSGS 54 % 76 % Summary Reduced remission induction period Increased serum albumin Increased serum albumin Effective in younger age Amelioration of ApoB deposition buy 5-Fluoracil in glomerulus 5 in 6 cases >50 % reduction of proteinuria in 9 cases Effective in PSL resistant juvenile patients Acknowledgments The {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| author would like to thank Drs. Soichi Sakai, Masatoshi Mune, Tsutomu Hirano, Motoshi Hattori, Kenjiro Kimura, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shunya Uchida, Takashi Wada, Tetsuo Shoji, Tsukasa Takemura, Yukio Yuzawa, Hiroaki Oda, Kiyoshi Mori, and Takao Saito for their support as members of the Sinomenine Japanese Society of Kidney and Lipids. The author also thanks Drs. Hitomi Miyata, Mari Maeda, and Hiroyuki Matsushima for their contributions to patient
care and related studies. Conflict of interest There is no conflict of interest in the preparation and submission of this manuscript. Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Sulowicz W, Stompor T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003;18:v59–62.PubMedCrossRef 2. Moorhead JF, Chan MK, El-Nahas M, et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2(8311):1309–11.PubMedCrossRef 3. Ong AC, et al. Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int. 1994;45:753–62.PubMedCrossRef 4. Sakurai M, Muso E, Matsushima H, Ono T, Sasayama S. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int Suppl. 1999;71:S210–2.PubMedCrossRef 5. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis.